Evidence map›Paper›PMID 37068907›Full record

Trial reportBMJ open2023

Identifying women who may benefit from higher dose omega-3 supplementation during pregnancy to reduce their risk of prematurity: exploratory analyses from the ORIP trial.

Lisa N Yelland, Thomas R Sullivan, Robert A Gibson, Lucy A Simmonds, Sagar K Thakkar, Fang Huang, Surabhi Devaraj, Karen P Best, Irma Silva Zolezzi, Maria Makrides

Open access · goldAbstract readRandomized Controlled TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BMJ open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
3.5field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 4 countries.

Lisa N YellandSAHMRI Women and Kids, South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia lisa.yelland@sahmri.com.ORCID 0000-0003-3803-8728
Thomas R SullivanSAHMRI Women and Kids, South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia.ORCID 0000-0002-6930-5406
Robert A GibsonSAHMRI Women and Kids, South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia.
Lucy A SimmondsCollege of Business, Government and Law, Flinders University, Adelaide, South Australia, Australia.ORCID 0000-0002-4795-5141
Sagar K ThakkarScientific Affairs, Nestlé Product Technology Center-Nutrition, Société des Produits Nestlé S.A, Vevey, Switzerland.
Fang HuangNestlé Research, Société des Produits Nestlé S.A, Beijing, China.
Surabhi DevarajNestlé Research, Société des Produits Nestlé S.A, Singapore.
Karen P BestSAHMRI Women and Kids, South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia.
Irma Silva ZolezziNestlé Product Technology Center-Nutrition, Société des Produits Nestlé S.A, Vevey, Switzerland.
Maria MakridesSAHMRI Women and Kids, South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia.
South Australian Health and Medical Research Institute · AUNestlé (Switzerland) · CHFlinders University · AUNestlé (China) · CNNestlé (Singapore) · SG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThe risk factors for prematurity are multifactorial and include low omega-3 status. Omega-3 supplementation in pregnancy has been found to reduce prematurity risk, particularly among women with low omega-3 levels. This study aimed to identify maternal characteristics that predict whether women with a singleton pregnancy will benefit from omega-3 supplementation to reduce their risk of prematurity.

designExploratory analyses of a multicentre, double-blind randomised trial.

setting6 tertiary care centres in four states in Australia.

participants5328 singleton pregnancies in 5305 women recruited before 20 weeks of gestation.

interventionsFish oil capsules containing 900 mg omega-3 long-chain polyunsaturated fatty acids per day versus vegetable oil capsules consumed from enrolment until 34 weeks' gestation. OUTCOME MEASURES: Early preterm birth (EPTB, <34 weeks' gestation) and preterm birth (PTB, <37 weeks' gestation) analysed using logistic regression models with interactions between treatment group and a range of maternal biological, clinical and demographic characteristics.

resultsOmega-3 supplementation reduced the odds of EPTB for women with low total omega-3 status in early pregnancy (OR=0.30, 95% CI 0.10-0.93). No additional maternal characteristics influenced whether omega-3 supplementation reduced the odds of EPTB. For PTB, women were more likely to benefit from omega-3 supplementation if they were multiparous (OR=0.65, 95% CI 0.49-0.87) or avoided alcohol in the lead up to pregnancy (OR=0.62, 95% CI 0.45-0.86).

conclusionsOur results support previous findings that women with low total omega-3 levels in early pregnancy are most likely to benefit from taking omega-3 supplements to reduce their risk of EPTB. Understanding how other maternal characteristics influence the effectiveness of omega-3 supplementation on reducing PTB requires further investigation. TRIAL REGISTRATION NUMBER: ACTRN12613001142729.

Indexed as

Fatty Acids, Omega-3Premature BirthDietary SupplementsFemaleFish OilsGestational AgeHumansInfant, NewbornPregnancyFatty Acids, Omega-3Fish OilsNEONATOLOGYNUTRITION & DIETETICSOBSTETRICSPUBLIC HEALTH

Identifiers

PMID37068907
PMCPMC10111924
OpenAlexW4366084679

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.